News & Updates
Filter by Specialty:
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
27 Nov 2022
Alprazolam safe, effective for controlling seizures
The use of alprazolam leads to rapid termination of seizures in patients with focal and/or generalized epilepsy treated in an inpatient setting, according to the results of the phase II study ENGAGE-E-001.
Alprazolam safe, effective for controlling seizures
26 Nov 2022
Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
Although the incidence of myocarditis or pericarditis following mRNA COVID-19 vaccination is low, a two- to threefold higher likelihood is seen among individuals who received mRNA-1273 compared to BNT162b2 vaccine, reveals a study.
Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
26 Nov 2022
Extended-release morphine of no benefit to COPD patients with breathlessness
A week-long treatment course of low-dose, extended-release morphine does not appear to be effective at relieving breathlessness in patients with chronic obstructive pulmonary disease (COPD), according to a study.
Extended-release morphine of no benefit to COPD patients with breathlessness
25 Nov 2022
Immunosuppressant exposure tied to guideline-congruent cervical cancer screening
Guideline-congruent screening for cervical cancer remains poor in women with systemic lupus erythematosus (SLE), according to a study.
Immunosuppressant exposure tied to guideline-congruent cervical cancer screening
24 Nov 2022
GLP-1 receptor agonists halt COPD exacerbations in T2D patients
Use of glucagon-like peptide 1 (GLP-1) receptor agonists or sodium-glucose co-transporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, helps prevent severe exacerbations of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes (T2D), a UK study has shown.